News | November 22, 2010

Study Shows Safety and Effectiveness for Abdominal Aortic Aneurysm Stent System


November 22, 2010 - An implantable medical device used in the minimally invasive treatment of abdominal aortic aneurysms delivered strong results through one year of patient follow-up in a U.S. pivotal study. The trial data, which was presented at the VEITHsymposium, looked at the Endurant Stent Graft System, by Medtronic.

In the study, the Endurant System was associated with no post-operative aneurysm ruptures or aneurysm-related mortalities at one year, and there were no mortalities from any cause at 30 days.

“The clinical results with Medtronic’s Endurant Stent Graft System out to one year in this study are quite encouraging,” Michel Makaroun, M.D., the study’s principal investigator, professor and chief of vascular surgery for the University of Pittsburgh School of Medicine. “Based on this data, the Endurant Stent Graft, with its low-profile delivery system and accurate deployment, appears to be safe and effective in the short term. It will prove to be a great addition to the currently available devices in the management of abdominal aortic aneurysms for a wide range of patients.”

The study included patients with “landing zones,” or healthy aortic neck lengths, as short as 10 mm, whereas most other trials of aortic stent grafts have required neck lengths of at least 15 mm.

The study monitored changes in aneurysm size and stent graft migration, a concern with current endovascular treatment. Nearly half (47.1 percent) of the aneurysm sacs that were treated with the Endurant Stent Graft System in the study decreased in size between one month and one year post-procedure, and none of the sacs increased in size. The rest (52.9 percent) remained stable in size during the same time period. In addition, none of the stent grafts migrated from their original placement.

The study also monitored the occurrence and type of endoleaks, which can result in persistent blood flow into the aneurysm sac. Through one year post-implant, there were no Type I or III endoleaks.

It received the CE mark in July 2008. The system is an investigational device in the United States.

For more information: www.medtronic.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now